English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/170764
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease

AuthorsLópez-Millán, Belén; Díaz de la Guardia, Rafael; Roca-Ho, Heleia; García-Herrero, Carmen-María; Lavoie, Jessie R.; Rosu-Myles, Michael; González-Rey, Elena; O'Valle, Francisco; Criado, Gabriel; Delgado, M.; Menéndez, Pablo
Issue Date3-Feb-2017
PublisherSpringer Nature
CitationExperimental and Molecular Medicine
AbstractThalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases.
URIhttp://hdl.handle.net/10261/170764
DOI10.1038/emm.2016.143
ISSN1226-3613
E-ISSN2092-6413
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
Therapeutic_emm2016143.pdfOriginal article1,71 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.